The company's average rating is Hold from 8 analysts.
Our investment recommendation tool can cross-verify current
analyst consensus on Karyopharm Therapeut and to analyze the entity potential to grow in the current economic cycle.
The performance of Karyopharm Therapeutics in the marketplace will significantly impact your decision to invest in its stock. Revenue growth, profitability, competitive positioning, management quality, and industry trends can influence Karyopharm Therapeutics'
stock prices. When investing in Karyopharm Therapeutics, there are several factors to consider and potential outcomes to expect. As a company performs well, its stock price may increase, allowing investors to benefit from price appreciation. However, Karyopharm Stock can experience significant price fluctuations due to market conditions, economic factors, industry trends, or company-specific news. This is why investing in stocks such as Karyopharm Therapeutics carries risks, including the potential for capital loss. Stock prices can decline, and investors may incur losses if they sell shares at a lower price than their initial investment.
Watch out for price decline
Please consider monitoring Karyopharm Therapeutics on a daily basis if you are holding a position in it. Karyopharm Therapeutics is trading at a penny-stock level, and the possibility of delisting is much higher compared to other stocks. However, just because the stock is trading under one dollar, does not mean it will be marked for deletion.
Most exchanges require public instruments, such as Karyopharm Therapeutics stock to be traded above the $1 level to remain listed. If Karyopharm Therapeutics stock price falls below $1 for 30 consecutive trading days, the exchange can delist it. Once the company reaches this point, they will be sent an initial price violation notice directly from an exchange.
How important is Karyopharm Therapeutics's Liquidity
Karyopharm Therapeutics
financial leverage refers to using borrowed capital as a funding source to finance Karyopharm Therapeutics ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Karyopharm Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Karyopharm Therapeutics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Karyopharm Therapeutics' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Karyopharm Therapeutics's total debt and its cash.
What do experts say about Karyopharm?
Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
Analysis ConsensusDetailed Perspective On Karyopharm Therapeutics
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Karyopharm Therapeut has an asset utilization ratio of 64.62 percent. This implies that the company is making $0.65 for each dollar of assets. An increasing asset utilization means that Karyopharm Therapeut is more efficient with each dollar of assets it utilizes for everyday operations.
| 2010 | 2020 | 2021 | 2022 (projected) |
Receivables | 7.86 M | 12.88 M | 11.59 M | 10.47 M | Inventories | 346 K | 2.64 M | 2.38 M | 1.88 M |
Are Karyopharm Therapeut technical ratios showing a collapse?
Standard deviation is down to 5.89. It may hint to a possible volatility drop. Karyopharm Therapeut exhibits above-average semi-deviation for your current time horizon. We encourage investors to investigate Karyopharm Therapeut individually to make sure intended market timing strategies and available technical indicagtors are consistent with their estimates about Karyopharm Therapeut future systematic risk. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Karyopharm Therapeut's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Karyopharm Therapeut's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Karyopharm Therapeut Implied Volatility
Karyopharm Therapeut's implied volatility exposes the market's sentiment of Karyopharm Therapeut stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Karyopharm Therapeut's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Karyopharm Therapeut stock will not fluctuate a lot when Karyopharm Therapeut's options are near their expiration.
Our Conclusion on Karyopharm Therapeut
While few other entities under the biotechnology industry are still a bit expensive, Karyopharm Therapeut may offer a potential longer-term growth to stockholders. With a relatively neutral outlook on the current economy, it is better to hold off any trading of Karyopharm as the current risk-reward utility is not appealing enough. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Karyopharm Therapeut.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Raphi Shpitalnik is a Junior Member of Macroaxis Editorial Board. Raphael is a young entrepreneur who joined Macroaxis on a part-time basis at the beginning of the pandemic and eventually acquired a real taste for investing and fintech. He likes to analyze different equity instruments across a wide range of industries, focusing primarily on consumer products, sports, fintech, cannabis, and AI.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Karyopharm Therapeutics. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
